Literature DB >> 12111199

E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?

Annette M Müller1, Andreas Weichert, Klaus-Michael Müller.   

Abstract

Pleural mesotheliomas, especially pure epithelioid mesotheliomas, may histologically be easily confused with peripheral pulmonary adenocarcinomas or pleural carcinosis. As there is no specific antibody for mesotheliomas, today a panel of immunohistochemical markers is used for the differential diagnosis of these two tumour entities. In search of further significant antibodies for application onto formalin-fixed, paraffin-embedded tissue, we immunohistochemically investigated the expression pattern of three adhesion molecules: vascular cell adhesion molecule (VCAM), E-selectin and E-cadherin. A comparatively large number of 44 mesotheliomas (15 epithelioid, 15 biphasic, 14 sarcomatoid) and 18 peripheral pulmonary adenocarcinomas were analysed. While for these two tumour entities there were no significant differences of the staining patterns for VCAM and E-selectin, there were significant differences in the expression of E-cadherin: while nearly all adenocarcinomas stained positively, there was almost no staining reaction of the mesotheliomas. Therefore, E-cadherin -- in contrast to E-selectin and VCAM -- appears to be a further relevant immunohistochemical marker for the distinction between adenocarcinomas and mesotheliomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12111199     DOI: 10.1007/s00428-001-0563-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  7 in total

1.  Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.

Authors:  Y Soini; V Kinnula; K Kahlos; P Pääkkö
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

2.  Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma.

Authors:  Yong-Bin Ding; Guo-Yu Chen; Jian-Guo Xia; Xi-Wei Zang; Hong-Yu Yang; Li Yang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Pathologic evaluation of tumor-associated macrophage density and vessel inflammation in invasive breast carcinomas.

Authors:  Yoshihiro Morita; Roy Zhang; Macall Leslie; Smita Adhikari; Nafis Hasan; Inna Chervoneva; Hallgeir Rui; Takemi Tanaka
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

Review 4.  Selectins-The Two Dr. Jekyll and Mr. Hyde Faces of Adhesion Molecules-A Review.

Authors:  Igor Tvaroška; Chandrabose Selvaraj; Jaroslav Koča
Journal:  Molecules       Date:  2020-06-19       Impact factor: 4.411

5.  Sialic acid-engineered mesoporous polydopamine dual loaded with ferritin gene and SPIO for achieving endogenous and exogenous synergistic T2-weighted magnetic resonance imaging of HCC.

Authors:  Kai Fan; Chengying Lu; Gaofeng Shu; Xiu-Ling Lv; Enqi Qiao; Nannan Zhang; Minjiang Chen; Jingjing Song; Fazong Wu; Zhongwei Zhao; Xiaoling Xu; Min Xu; Chunmiao Chen; Weibin Yang; Jihong Sun; Yongzhong Du; Jiansong Ji
Journal:  J Nanobiotechnology       Date:  2021-03-17       Impact factor: 10.435

6.  Invasive Breast Carcinoma with Abundant Collagenous Stroma Shows Lower Level of CD68-Positive Tumor Associated Macrophages than Those of Invasive Carcinoma without Abundant Collagenous Stroma.

Authors:  Canan Kelten Talu; Ezgi Hacihasanoglu; Cem Leblebici; Mehmet Ali Nazli; Esra Arslan; Didem Can Trabulus
Journal:  Acta Biomed       Date:  2021-11-03

7.  Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer.

Authors:  Yoshihiro Morita; Macall Leslie; Hiroyasu Kameyama; Ganesh L R Lokesh; Norihisa Ichimura; Rachel Davis; Natalie Hills; Nafis Hasan; Roy Zhang; Yuji Kondo; David G Gorenstein; David E Volk; Inna Chervoneva; Hallgeir Rui; Takemi Tanaka
Journal:  Cancers (Basel)       Date:  2020-03-19       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.